2023. 3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s142. DOI:https://doi.org/10.25251/skin.7.supp.142.